Karine Lacombe to Humans
This is a "connection" page, showing publications Karine Lacombe has written about Humans.
Connection Strength
0.130
-
Emerging RNA-Dependent RNA Polymerase Mutation in a Remdesivir-Treated B-cell Immunodeficient Patient With Protracted Coronavirus Disease 2019. Clin Infect Dis. 2021 10 05; 73(7):e1762-e1765.
Score: 0.008
-
Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. Blood. 2020 11 12; 136(20):2290-2295.
Score: 0.007
-
[Hepatitis B virus infection: Natural history, clinical manifestations and therapeutic approach]. Rev Med Interne. 2019 Sep; 40(9):590-598.
Score: 0.007
-
HCV core antigen: toward elimination of nucleic acid testing? Lancet Gastroenterol Hepatol. 2018 12; 3(12):817-818.
Score: 0.006
-
Research gaps in viral hepatitis. J Int AIDS Soc. 2018 04; 21 Suppl 2:e25054.
Score: 0.006
-
Innovative technologies for point-of-care testing of viral hepatitis in low-resource and decentralized settings. J Viral Hepat. 2018 02; 25(2):108-117.
Score: 0.006
-
Testing for hepatitis B virus alone does not increase vaccine coverage in non-immunized persons. World J Gastroenterol. 2017 Oct 14; 23(38):7037-7046.
Score: 0.006
-
Development of anti-hepatitis B surface (HBs) antibodies after HBs antigen loss in HIV-hepatitis B virus co-infected patients. J Clin Virol. 2017 10; 95:55-60.
Score: 0.006
-
HCV Ag quantification as a one-step procedure in diagnosing chronic hepatitis C infection in Cameroon: the ANRS 12336 study. J Int AIDS Soc. 2017 05 15; 20(1):21446.
Score: 0.006
-
Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort. J Acquir Immune Defic Syndr. 2017 05 01; 75(1):97-107.
Score: 0.006
-
Liver fibrosis regression and progression during controlled hepatitis B virus infection among HIV-HBV patients treated with tenofovir disoproxil fumarate in France: a prospective cohort study. J Int AIDS Soc. 2017 02 28; 20(1):21426.
Score: 0.006
-
Tocilizumab in Coronavirus Disease 2019: Give It Time! Clin Infect Dis. 2021 12 16; 73(12):2368-2369.
Score: 0.002
-
Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study. Antimicrob Agents Chemother. 2021 08 17; 65(9):e0123721.
Score: 0.002
-
Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies. Ann Oncol. 2021 11; 32(11):1445-1447.
Score: 0.002
-
Tocilizumab and COVID-19: Timing of administration assessment. Infect Dis Now. 2022 Feb; 52(1):31-34.
Score: 0.002
-
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-ß-1a and hydroxychloroquine in hospitalized patients with COVID-19. Clin Microbiol Infect. 2021 Dec; 27(12):1826-1837.
Score: 0.002
-
Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy. Am J Hematol. 2021 08 01; 96(8):934-944.
Score: 0.002
-
Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial. Trials. 2021 Mar 09; 22(1):199.
Score: 0.002
-
A look-back at convalescent plasma to treat COVID-19. Transfus Apher Sci. 2021 02; 60(1):103063.
Score: 0.002
-
Severe COVID-19 infection in a patient with paroxysmal nocturnal hemoglobinuria on eculizumab therapy. Leuk Lymphoma. 2021 06; 62(6):1502-1505.
Score: 0.002
-
Usefulness of Plasma SARS-CoV-2 RNA Quantification by Droplet-based Digital PCR to Monitor Treatment Against COVID-19 in a B-cell Lymphoma Patient. Stem Cell Rev Rep. 2021 02; 17(1):296-299.
Score: 0.002
-
Cyber harassment of female scientists will not be the new norm. Lancet Infect Dis. 2021 04; 21(4):457-458.
Score: 0.002
-
[COVID-19: Still a place for tocilizumab?] Rev Med Interne. 2021 02; 42(2):73-78.
Score: 0.002
-
Severe COVID-19 in Patients with B Cell Alymphocytosis and Response to Convalescent Plasma Therapy. J Clin Immunol. 2021 02; 41(2):356-361.
Score: 0.002
-
Converging pandemics: implications of COVID-19 for the viral hepatitis response in sub-Saharan Africa. Lancet Gastroenterol Hepatol. 2020 07; 5(7):634-636.
Score: 0.002
-
Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International Study. Clin Infect Dis. 2020 05 23; 70(11):2369-2376.
Score: 0.002
-
Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how? Vox Sang. 2020 Aug; 115(6):488-494.
Score: 0.002
-
Liver stiffness and fibrosis-4 alone better predict liver events compared with aspartate aminotransferase to platelet ratio index in a cohort of human immunodeficiency virus and hepatitis C virus co-infected patients from ANRS CO13 HEPAVIH cohort. Eur J Gastroenterol Hepatol. 2019 Nov; 31(11):1387-1396.
Score: 0.002
-
Chlamydia trachomatis screening in urine among asymptomatic men attending an STI clinic in Paris: a cross-sectional study. BMC Infect Dis. 2019 Jan 08; 19(1):31.
Score: 0.002
-
Confirmation of HCV viremia using HCV RNA and core antigen testing on dried blood spot in HIV infected peoples who inject drugs in Vietnam. BMC Infect Dis. 2018 Dec 04; 18(1):622.
Score: 0.002
-
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. Int J Drug Policy. 2018 12; 62:94-103.
Score: 0.002
-
Reply to Hector et al. Clin Infect Dis. 2018 09 28; 67(8):1311-1312.
Score: 0.002
-
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study. Clin Infect Dis. 2018 09 14; 67(7):1010-1017.
Score: 0.002
-
Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals. AIDS. 2018 09 10; 32(14):1995-2004.
Score: 0.002
-
Precore G1896A mutation is associated with reduced rates of HBsAg seroclearance in treated HIV hepatitis B virus co-infected patients from Western Africa. J Viral Hepat. 2018 10; 25(10):1121-1131.
Score: 0.002
-
Linkage and retention in HCV care for HIV-infected populations: early data from the DAA era. J Int AIDS Soc. 2018 04; 21 Suppl 2:e25051.
Score: 0.002
-
CD4+ T Cell Recovery and Hepatitis B Virus Coinfection in HIV-Infected Patients from Côte d'Ivoire Initiating Antiretroviral Therapy. AIDS Res Hum Retroviruses. 2018 05; 34(5):439-445.
Score: 0.002
-
Higher Mortality Despite Early Antiretroviral Therapy in Human Immunodeficiency Virus and Hepatitis B Virus (HBV)-Coinfected Patients With High HBV Replication. Clin Infect Dis. 2018 01 06; 66(1):112-120.
Score: 0.001
-
Uptake of tenofovir-based antiretroviral therapy among HIV-HBV-coinfected patients in the EuroSIDA study. Antivir Ther. 2018; 23(5):405-413.
Score: 0.001
-
Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study). HIV Med. 2018 03; 19(3):227-237.
Score: 0.001
-
Low incidence of precore W28* mutant variants in treated hepatitis B virus and human immunodeficiency virus co-infected patients. Antiviral Res. 2018 01; 149:174-178.
Score: 0.001
-
The impact of coffee consumption on fibrosis and steatosis in HIV-HCV co-infected patients. J Hepatol. 2018 04; 68(4):845-847.
Score: 0.001
-
Clinical Outcomes during Treatment Interruptions in Human Immunodeficiency Virus-Hepatitis B Virus Co-infected Patients from Sub-Saharan Africa. Am J Trop Med Hyg. 2017 Dec; 97(6):1936-1942.
Score: 0.001
-
Metabolic syndrome and obesity are the cornerstones of liver fibrosis in HIV-monoinfected patients. AIDS. 2017 09 10; 31(14):1955-1964.
Score: 0.001
-
Diagnostic accuracy of the Coopscore© to predict liver fibrosis in human immunodeficiency virus/hepatitis B virus co-infection. Ann Clin Biochem. 2018 Mar; 55(2):236-243.
Score: 0.001
-
Hepatitis C virus drives increased type I interferon-associated impairments associated with fibrosis severity in antiretroviral treatment-treated HIV-1-hepatitis C virus-coinfected individuals. AIDS. 2017 06 01; 31(9):1223-1234.
Score: 0.001
-
Potential effect of lamivudine-induced S gene mutations on liver-related pathogenesis in hepatitis D virus infection. Hepatology. 2017 04; 65(4):1424-1426.
Score: 0.001
-
Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort. J Hepatol. 2017 07; 67(1):23-31.
Score: 0.001